Cargando…

Neurodegeneration in type 2 diabetes: Alzheimer's as a case study

INTRODUCTION: Rigorous research in the last few years has shown that in addition to the classical mechanism of neurodegeneration, certain unconventional mechanisms may also lead to neurodegenerative disease. One of them is a widely studied metabolic disorder: type 2 diabetes mellitus (T2DM). We now...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhusudhanan, Jalaja, Suresh, Gowthaman, Devanathan, Vasudharani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218246/
https://www.ncbi.nlm.nih.gov/pubmed/32170854
http://dx.doi.org/10.1002/brb3.1577
_version_ 1783532759989354496
author Madhusudhanan, Jalaja
Suresh, Gowthaman
Devanathan, Vasudharani
author_facet Madhusudhanan, Jalaja
Suresh, Gowthaman
Devanathan, Vasudharani
author_sort Madhusudhanan, Jalaja
collection PubMed
description INTRODUCTION: Rigorous research in the last few years has shown that in addition to the classical mechanism of neurodegeneration, certain unconventional mechanisms may also lead to neurodegenerative disease. One of them is a widely studied metabolic disorder: type 2 diabetes mellitus (T2DM). We now have a clear understanding of glucose‐mediated neurodegeneration, mostly from studies in Alzheimer's disease (AD) models. AD is recognized to be significantly associated with hyperglycemia, even earning the term “type 3 diabetes.” Here, we review first the pathophysiology of AD, both from the perspective of classical protein accumulation, as well as the newer T2DM‐dependent mechanisms supported by findings from patients with T2DM. Secondly, we review the different pathways through which neurodegeneration is aggravated in hyperglycemic conditions taking AD as a case study. Finally, some of the current advances in AD management as a result of recent research developments in metabolic disorders‐driven neurodegeneration are also discussed. METHODS: Relevant literatures found from PubMed search were reviewed. RESULTS: Apart from the known causes of AD, type 2 diabetes opens a new window to the AD pathology in several ways. It is a bidirectional interaction, of which, the molecular and signaling mechanisms are recently studied. This is our attempt to connect all of them to draw a complete mechanistic explanation for the neurodegeneration in T2DM. Refer to Figure 3. CONCLUSION: The perspective of AD as a classical neurodegenerative disease is changing, and it is now being looked at from a zoomed‐out perspective. The correlation between T2DM and AD is something observed and studied extensively. It is promising to know that there are certain advances in AD management following these studies.
format Online
Article
Text
id pubmed-7218246
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72182462020-05-13 Neurodegeneration in type 2 diabetes: Alzheimer's as a case study Madhusudhanan, Jalaja Suresh, Gowthaman Devanathan, Vasudharani Brain Behav Review Article INTRODUCTION: Rigorous research in the last few years has shown that in addition to the classical mechanism of neurodegeneration, certain unconventional mechanisms may also lead to neurodegenerative disease. One of them is a widely studied metabolic disorder: type 2 diabetes mellitus (T2DM). We now have a clear understanding of glucose‐mediated neurodegeneration, mostly from studies in Alzheimer's disease (AD) models. AD is recognized to be significantly associated with hyperglycemia, even earning the term “type 3 diabetes.” Here, we review first the pathophysiology of AD, both from the perspective of classical protein accumulation, as well as the newer T2DM‐dependent mechanisms supported by findings from patients with T2DM. Secondly, we review the different pathways through which neurodegeneration is aggravated in hyperglycemic conditions taking AD as a case study. Finally, some of the current advances in AD management as a result of recent research developments in metabolic disorders‐driven neurodegeneration are also discussed. METHODS: Relevant literatures found from PubMed search were reviewed. RESULTS: Apart from the known causes of AD, type 2 diabetes opens a new window to the AD pathology in several ways. It is a bidirectional interaction, of which, the molecular and signaling mechanisms are recently studied. This is our attempt to connect all of them to draw a complete mechanistic explanation for the neurodegeneration in T2DM. Refer to Figure 3. CONCLUSION: The perspective of AD as a classical neurodegenerative disease is changing, and it is now being looked at from a zoomed‐out perspective. The correlation between T2DM and AD is something observed and studied extensively. It is promising to know that there are certain advances in AD management following these studies. John Wiley and Sons Inc. 2020-03-14 /pmc/articles/PMC7218246/ /pubmed/32170854 http://dx.doi.org/10.1002/brb3.1577 Text en © 2020 Indian Institute of Science Education and Research (IISER), Tirupati. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Madhusudhanan, Jalaja
Suresh, Gowthaman
Devanathan, Vasudharani
Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title_full Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title_fullStr Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title_full_unstemmed Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title_short Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
title_sort neurodegeneration in type 2 diabetes: alzheimer's as a case study
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218246/
https://www.ncbi.nlm.nih.gov/pubmed/32170854
http://dx.doi.org/10.1002/brb3.1577
work_keys_str_mv AT madhusudhananjalaja neurodegenerationintype2diabetesalzheimersasacasestudy
AT sureshgowthaman neurodegenerationintype2diabetesalzheimersasacasestudy
AT devanathanvasudharani neurodegenerationintype2diabetesalzheimersasacasestudy